US6077509A
(en)
*
|
1990-03-30 |
2000-06-20 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
US5800808A
(en)
*
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
IL137761A0
(en)
*
|
1998-02-13 |
2001-10-31 |
Autoimmune Inc |
Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
EP1098902A4
(en)
|
1998-07-23 |
2002-07-24 |
Yeda Res & Dev |
TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
EP2090583B1
(en)
|
1998-09-25 |
2011-07-13 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
WO2005046719A1
(en)
|
2003-11-12 |
2005-05-26 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
US6844314B2
(en)
*
|
2000-01-20 |
2005-01-18 |
Yeda Research Development Co., Ltd. |
Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
|
JP2003522799A
(ja)
*
|
2000-02-18 |
2003-07-29 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス |
コポリマー1の経口、経鼻および経肺投与製剤
|
US7022663B2
(en)
*
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
AU7528001A
(en)
*
|
2000-06-05 |
2001-12-17 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
DK1294390T3
(da)
*
|
2000-06-07 |
2006-04-03 |
Yeda Res & Dev |
Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
|
WO2002076503A1
(en)
*
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
WO2001097785A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Caprion Pharmaceuticals Inc. |
Basic copolymers for the treatment of prion-related-disease
|
IL137460A0
(en)
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
MXPA04005433A
(es)
*
|
2001-12-04 |
2004-10-11 |
Teva Pharma |
Proceso para la medicion de la potencia de acetato de glatiramero.
|
DK1429800T3
(da)
*
|
2001-12-06 |
2009-04-27 |
Yeda Res & Dev |
Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
|
AU2002360696A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
US20070248569A1
(en)
|
2003-01-07 |
2007-10-25 |
Michal Eisenbach-Schwartz |
Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization
|
US8008258B2
(en)
*
|
2003-01-21 |
2011-08-30 |
Yeda Research And Development Co. Ltd. |
Cop 1 for treatment of inflammatory bowel diseases
|
CA2518079A1
(en)
*
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
JP2006522135A
(ja)
|
2003-03-31 |
2006-09-28 |
ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド |
喘息およびアレルギーの処置のための両性イオン免疫調節剤
|
CA2541445A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Teva Pharmaceutical Industries Ltd. |
Nanoparticles for drug delivery
|
PL1701730T3
(pl)
|
2003-12-09 |
2014-04-30 |
Yeda Res & Dev |
Sposób i szczepionka zawierająca kopolimer 1 do leczenia zaburzeń psychicznych
|
EP1725099A4
(en)
*
|
2004-02-02 |
2009-08-19 |
Mixture Sciences Inc |
MIXTURES OF PEPTIDES WITH IMMUNOMODULATORY ACTIVITY
|
AU2005219876A1
(en)
*
|
2004-03-01 |
2005-09-15 |
Peptimmune, Inc. |
Methods and compositions for treatment of autoimmune diseases
|
US20070244056A1
(en)
*
|
2004-03-03 |
2007-10-18 |
Liat Hayardeny |
Combination Therapy With Glatiramer Acetate and Riluzole
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
JP2007536278A
(ja)
|
2004-05-07 |
2007-12-13 |
ペプチミューン,インコーポレイテッド |
ランダム共重合体を用いる疾患の治療方法
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
JP5274011B2
(ja)
|
2004-06-25 |
2013-08-28 |
アイディー バイオメディカル コーポレイション オブ ケベック |
神経障害を治療するための組成物および方法
|
WO2006029411A2
(en)
*
|
2004-09-09 |
2006-03-16 |
Yeda Research And Development Co. Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
ATE536363T1
(de)
|
2004-09-09 |
2011-12-15 |
Teva Pharma |
Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
AU2005302500B2
(en)
*
|
2004-10-29 |
2008-11-27 |
Sandoz Ag |
Processes for preparing glatiramer
|
CA2588908C
(en)
*
|
2004-11-29 |
2014-09-23 |
Yeda Research And Development Co. Ltd |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
EP1838326A4
(en)
*
|
2005-02-02 |
2009-09-30 |
Teva Pharma |
PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS
|
PT1848415E
(pt)
*
|
2005-02-17 |
2013-06-27 |
Teva Pharma |
Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
US20060240463A1
(en)
*
|
2005-04-25 |
2006-10-26 |
Rappaport Family Institute For Research In The Medical Sciences |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
WO2007092451A2
(en)
|
2006-02-06 |
2007-08-16 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
WO2007120834A2
(en)
|
2006-04-13 |
2007-10-25 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
CA2650653C
(en)
|
2006-04-28 |
2016-03-29 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating glatiramer acetate
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
EP2046366B1
(en)
|
2006-06-28 |
2016-08-31 |
Yeda Research And Development Company Limited |
Copolymer-1 for treatment of age-related macular degeneration
|
ES2338488T3
(es)
*
|
2006-07-05 |
2010-05-07 |
Momenta Pharmaceuticals, Inc. |
Proceso mejorado para la preparacion de copolimero-1.
|
ES2477232T5
(es)
|
2007-06-21 |
2017-11-23 |
Momenta Pharmaceuticals, Inc. |
Análisis de copolímeros
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
EP2173766A1
(en)
*
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
BRPI0817682A2
(pt)
|
2007-10-16 |
2015-04-07 |
Peptimmune Inc |
Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos
|
WO2009062132A2
(en)
|
2007-11-09 |
2009-05-14 |
California Institute Of Technology |
Immunomodulating compounds and related compositions and methods
|
AU2008330093A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Yeda Research And Development Co., Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
RU2010146489A
(ru)
|
2008-04-16 |
2012-05-27 |
Момента Фармасьютикалз, Инк. (Us) |
Анализ композиций сополимера аминокислот
|
ES2537022T3
(es)
*
|
2008-08-07 |
2015-06-01 |
Sigma-Aldrich Co. Llc |
Preparación de polilisina y poliornitina de bajo peso molecular con alto rendimiento
|
WO2010017292A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
US9617313B2
(en)
*
|
2008-12-24 |
2017-04-11 |
Synthon Bv |
Process for purifying a polymer mixture
|
WO2010115175A1
(en)
|
2009-04-03 |
2010-10-07 |
Momenta Pharmaceticals, Inc. |
Control of copolymer compositions
|
AU2009347384B2
(en)
*
|
2009-06-04 |
2014-10-23 |
Council Of Scientific & Industrial Research |
A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
CA2697570C
(en)
*
|
2009-07-15 |
2011-11-01 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
RS52885B
(en)
|
2009-08-20 |
2014-02-28 |
Yeda Research And Development Co. Ltd. |
LOW-FREQUENCY GLATIRAMER ACETATOM THERAPY
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
CN102686235A
(zh)
|
2010-01-04 |
2012-09-19 |
Mapi医药公司 |
包含格拉默或其药用盐的储药系统
|
WO2011086470A1
(en)
|
2010-01-13 |
2011-07-21 |
Ramot At Tel-Aviv University Ltd |
Treatment of multiple sclerosis
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
ES2694100T3
(es)
|
2010-04-07 |
2018-12-18 |
California Institute Of Technology |
Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
|
AU2011248663A1
(en)
*
|
2010-04-27 |
2012-11-08 |
Dr. Reddy's Laboratories Ltd. |
Preparation of polypeptides and salts thereof
|
JP2013530949A
(ja)
|
2010-05-20 |
2013-08-01 |
エル ラウンド ジューン |
抗原特異的Treg並びに関連する組成物、方法及びシステム
|
KR20130043196A
(ko)
*
|
2010-07-29 |
2013-04-29 |
닥터 레디스 래보러토리즈, 인코포레이티드 |
글라티라머 아세테이트 분자량 마커
|
EA025780B1
(ru)
|
2010-10-11 |
2017-01-30 |
Тева Фармасьютикал Индастриз Лтд. |
Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
|
EP2675824B1
(en)
|
2011-02-14 |
2017-09-27 |
USV Private Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
WO2013009945A1
(en)
|
2011-07-12 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Lipid-containing psa compositions, methods of isolation and methods of use thereof
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
TW201326399A
(zh)
|
2011-10-10 |
2013-07-01 |
Teva Pharma |
用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
PL2774639T3
(pl)
|
2013-03-08 |
2015-07-31 |
Teva Pharma |
Wielorazowe urządzenie strzykawkowe dla strzykawki
|
DK2774640T3
(en)
|
2013-03-08 |
2015-02-02 |
Teva Pharma |
Reusable injection device for a syringe
|
AU2014244550B2
(en)
|
2013-03-14 |
2018-11-01 |
Mylan Inc. |
Glatiramer acetate response biomarker mRNA potency assay
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
JP2016521284A
(ja)
|
2013-05-10 |
2016-07-21 |
カリフォルニア インスティチュート オブ テクノロジー |
大腸ガンのプロバイオティクスによる防止および処置
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
TWI717314B
(zh)
|
2013-10-24 |
2021-02-01 |
美商麥蘭股份有限公司 |
供評估格拉默醋酸鹽製備物之免疫同一性用的人類t細胞株分析方法
|
JP2017503169A
(ja)
|
2013-12-31 |
2017-01-26 |
イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド |
オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
|
KR20200029627A
(ko)
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
EP3265814B1
(en)
|
2015-03-01 |
2020-11-18 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
WO2016201342A1
(en)
|
2015-06-10 |
2016-12-15 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
CA2997211A1
(en)
|
2015-08-19 |
2017-02-23 |
President And Fellows Of Harvard College |
Lipidated psa compositions and methods
|
ES2744179T3
(es)
|
2015-09-24 |
2020-02-24 |
Chemi Spa |
Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
|
EP3170836B1
(en)
|
2015-11-23 |
2018-10-24 |
Chemi SPA |
Rp-hplc analysis of complex polypeptide mixtures
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
EP3478300B1
(en)
|
2016-06-30 |
2022-08-24 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
WO2018014012A1
(en)
|
2016-07-15 |
2018-01-18 |
President And Fellows Of Harvard College |
Glycolipid compositions and methods of use
|
BR112019003131A2
(pt)
|
2016-08-28 |
2019-05-21 |
Mapi Pharma Ltd. |
processo para preparar micropartículas contendo acetato de glatirâmero
|
SI3506921T1
(sl)
|
2016-08-31 |
2023-10-30 |
Mapi Pharma Ltd. |
Depojski sistemi, ki vsebujejo glatiramer acetat
|
EP3600553A4
(en)
|
2017-03-26 |
2020-09-02 |
Mapi Pharma Ltd. |
GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
|
CA3062123A1
(en)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
JP7000458B2
(ja)
|
2017-05-15 |
2022-02-10 |
ステム セル メディスン リミテッド |
長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
|
EP3765034A1
(en)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Treatment of a heart disease
|